Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29811180 | 0.69 | ACLY (0.52) | ALDH1A1GLRA1SLC6A9OR51E2KDM4E | |
| SCHEMBL3794658 | 0.67 | KDM4E (0.41) | GABRR1ALDH1A1MAPTPTGS1KDM4E | |
| SCHEMBL19988095 | 0.67 | KDM4E (0.41) | GABRR1ALDH1A1MAPTPTGS1GLRA1 | |
| SCHEMBL17092532 | 0.67 | DPP4 (0.36) | — | |
| Hydrochloric Acid SCHEMBL2677291 | 0.65 | KDM4E (0.44) | GABRR1ALDH1A1MAPTPTGS1KDM4E | |
| Iodide SCHEMBL10424820 | 0.65 | KDM4E (0.39) | GABRR1ALDH1A1MAPTPTGS1KDM4E | |
| SCHEMBL28243171 | 0.65 | LMNA (0.32) | ALDH1A1TSHR | |
| SCHEMBL7416828 | 0.65 | GABRR1 (0.46) | GABRR1ALDH1A1MAPTPTGS1KDM4E | |
| SCHEMBL28609539 | 0.64 | — | — | |
| SCHEMBL498110 | 0.64 | ALDH1A1 (0.56) | ALDH1A1MAPTPTGS1TSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160324972-A1 | TREATMENT OF MENINGEAL AND NEURAL DISEASES | MASSACHUSETTS GEN HOSPITAL (US) | 2016-11-10 | — | — | US | disclosed |
| US-8546419-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120289535-A1 | DUAL PHASE DRUG RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120171118-A1 | TREATMENT OF MENINGEAL AND NEURAL DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2012-07-05 | — | — | US | disclosed |
| EP-1667726-B1 | POLYACETAL DRUG CONJUGATES AS RELEASE SYSTEM | GEN HOSPITAL CORP (US) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010144881-A1 | TREATMENT OF MENINGEAL AND NEURAL DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2010-12-16 | — | — | WO | disclosed |
| US-7790150-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070190018-A1 | Dual phase drug release system | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324972-A1 | TREATMENT OF MENINGEAL AND NEURAL DISEASES | AQP4, PMP22, MAG | GABRR1 1378/4885ALDH1A1 2125/4885MAPT 272/4885 |
| US-20120289535-A1 | DUAL PHASE DRUG RELEASE SYSTEM | SUCNR1, SUCLA2, SUMO2 | GABRR1 1573/4885ALDH1A1 835/4885MAPT 1957/4885 |
| US-20070190018-A1 | Dual phase drug release system | SUCNR1, SUCLA2, SUCLG2 | GABRR1 1909/4885ALDH1A1 490/4885MAPT 1545/4885 |
| US-20120171118-A1 | TREATMENT OF MENINGEAL AND NEURAL DISEASES | AQP4, PMP22, MAG | GABRR1 1378/4885ALDH1A1 2125/4885MAPT 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.